Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials

Fig. 2

Postprogression overall survival by treatment cohort. Kaplan–Meier curves of ppOS in a cobimetinib plus vemurafenib cohort, b vemurafenib monotherapy cohort, and c dacarbazine cohort. CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, IT immunotherapy, LDH lactate dehydrogenase, NE not estimable, PD progressive disease, ppOS postprogression overall survival, ppRx initial postprogression treatment, TT targeted therapy, ULN upper limit of normal

Back to article page